Patient-reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review by Sally Taylor, Kate Law, Jake Coomber-Moore, Michelle Davies, Fiona Thistlethwaite, Mel Calvert, Olalekan Aiyegbusi, Janelle Yorke

Get full text

Correction: Patient‑reported outcome (PRO) instruments used in patients undergoing adoptive cell therapy (ACT) for the treatment of cancer: a systematic review by Sally Taylor, Kate Law, Jake Coomber‑Moore, Michelle Davies, Fiona Thistlethwaite, Mel Calvert, Olalekan Aiyegbusi, Janelle Yorke

Get full text

Development and validation of a patient reported experience measure for experimental cancer medicines (PREM-ECM) and their carers (PREM-ECM-Carer) by Chelsea S. Sawyer, Sally Taylor, Louise Carter, Melissa Stanworth, Michelle Davies, Fiona Thistlethwaite, Jo Taylor, Charlotte Eastwood, Janelle Yorke

Get full text

Evidence of clinical efficacy of a first generation CD19 CAR T cell in B cell malignancies by Kyrillus S. Shohdy, Manon Pillai, Ryan Guest, Dominic Rothwell, Natalia Kirillova, Shien Chow, David Gilham, Fiona Thistlethwaite, Robert Hawkins

Get full text

Oncology patients’ experiences in experimental medicine cancer trials: a qualitative study by Janelle Yorke, Laurie Preston, Natalie Cook, Sally Taylor, Michelle Davies, Matthew Krebs, Fiona Thistlethwaite, Louise Carter, Chelsea Sawyer, Donna Graham

Get full text

Exploring the barriers to, and importance of, participant diversity in early-phase clinical trials: an interview-based qualitative study of professionals and patient and public rep... by Cindy Cooper, Katie Biggs, Alexander Rothman, Christina Yap, Fiona Thistlethwaite, Della Ogunleye, Munyaradzi Dimairo, Robin Chatters, Shamila Ditta, Jonathan Woodward

Get full text

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study by Omid Hamid, Fiona Thistlethwaite, Johanna Bendell, Ruth Plummer, Patrick A Ott, Rachel E Sanborn, Karen A Autio, Valentina Boni, Elisabeth GE de Vries, Javier Garcia-Corbacho, Daniel C Cho, Mark Stroh, Lawrence Lu

Get full text

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors by Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Noelia Martinez Jañez, Jose Trigo, Alastair Greystoke, R. Donald Harvey, Anthony J. Olszanski, Mateusz Opyrchal, Alexander Spira, Fiona Thistlethwaite, Begoña Jiménez, Jessica Huck Sappal, Karuppiah Kannan, Jason Riley, Cheryl Li, Cong Li, Richard C. Gregory, Harry Miao, Shining Wang

Get full text

CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study by Hendrik-Tobias Arkenau, Marta Gil-Martin, Fiona Thistlethwaite, Aung Naing, Karen A. Autio, Patrick A. Ott, Johanna Bendell, Patricia LoRusso, Valentina Boni, Alexander Spira, Javier Garcia-Corbacho, Mark Stroh, Elisabeth G.E. De Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Manreet Randhawa, Greg Durm, Alison L. Hannah

Get full text